Penicillin Allergy Delabeling Project (PenProv)
Primary Purpose
Penicillin Allergy
Status
Recruiting
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Risk stratification
Sponsored by
About this trial
This is an interventional diagnostic trial for Penicillin Allergy
Eligibility Criteria
Inclusion Criteria:
- Penicillin allergy in the patient journal oder patient reported
Exclusion Criteria:
- Not able to give concent. Under 16 years of age.
Sites / Locations
- Haukeland University HospitalRecruiting
- Helse Førde
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
Directly delabeled trough risk stratification tool
Low risk patients
High risk
Arm Description
Patients who are stratified as " no penicillin allergy" undergo a one dose full dose provocation test with 500 mg amoxicillin.
Patients stratified as low risk on penicillin provocation undergo a one dose full dose provocation test with 500mg amoxicillin
Patient stratified as high risk undergo a full allergologic work up, and only some of these will undergo a provocation test.
Outcomes
Primary Outcome Measures
Validating of a risk stratification tool ( in Norwegian) and advanced drug provocation challenge
Negative predictive value of the risk stratification tool
Analyzing the effects of risk stratification and advanced drug provocation
Change in number of patients with antibiotic treatment in line with government recommendation.
Analyzing the gut microbiome of patient labeled penicillin allergic
Map the gut microbiota profile in patients labeled penicillin allergic with 16S rRibosomal ribonucleic acid sequencing.
Secondary Outcome Measures
Change in days submitted to hospital before and after delabeling in the current ward.
number of days submittet to hospital
Number of patients with treatment related adverse events on oral provocation testing.
number of patients with treatment related adverse event on oral provocation testing.
Full Information
NCT ID
NCT05090527
First Posted
August 9, 2021
Last Updated
October 21, 2021
Sponsor
Haukeland University Hospital
Collaborators
Helse Fonna, Helse Forde
1. Study Identification
Unique Protocol Identification Number
NCT05090527
Brief Title
Penicillin Allergy Delabeling Project
Acronym
PenProv
Official Title
Penicillin Delabeling With Help of a Risk Stratification Tool, Advanced Provocation Tests in a Non Allergologic Unit and Examination of the Gut Microbiota in Patients Labeled Penicillin Allergic
Study Type
Interventional
2. Study Status
Record Verification Date
April 2021
Overall Recruitment Status
Recruiting
Study Start Date
July 28, 2021 (Actual)
Primary Completion Date
July 1, 2026 (Anticipated)
Study Completion Date
July 1, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Haukeland University Hospital
Collaborators
Helse Fonna, Helse Forde
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
A investigational study to establish:
A validated risk stratification tool for patients labeled Penicillin allergic.
Facilitate provocation test for delabeling of Penicillin allergy outside an allergologic clinic
Examine the gut microbiome of penicillin allergic patients
Detailed Description
Patients labeled penicillin allergic is a significant and growing public health problem. 10% of all patients report penicillin allergy. 9 out of 10 however tolerate penicillin on provocation, To be labeled as penicillin allergic has several well documented negative health outcomes for the individual, and on a public health scale.
One of the biggest obstacles in delabeling penicillin allergy is the lack of validated tools i Norwegian, the lack of in vitro tests for severe late /T cell mediated reactions and the accessibility of the gold standard procedure, drug provocation test.
In this study patients having a penicillin allergy label will after giving their written concent be screened used a risk stratification tool. The low risk patient will then directly undergo a single full dose amoxicillin challenge. High risk patients are refered to a allergologic clinic and undergoes full allergologic examination. The investigators seek to document that in low risk patients is a single dose Amoxicillin challenge safe and beneficial outside an allergologic clinic, and to validate the risk stratification tool in Norwegian.
The investigators want to examine the gut microbiome of patients labeled penicillin allergic. Changes in the gut microbiome can be temporarily and permanent, and selected microbiome profiles has shown to influence the health outcome of patients. Little is known about the impact on the gut microbiome in patients labeled penicillin allergic and the examinators seek to examine this, and correlate data with known risk profiles in gut microbiome.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Penicillin Allergy
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Model Description
Entry criteria: Penicillin allergy noted in patients journal or patient reported.
Masking
None (Open Label)
Masking Description
None, open provocation test with amoxicillin for eligible patients after risk stratification with a questionnaire.
Allocation
Non-Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Directly delabeled trough risk stratification tool
Arm Type
Active Comparator
Arm Description
Patients who are stratified as " no penicillin allergy" undergo a one dose full dose provocation test with 500 mg amoxicillin.
Arm Title
Low risk patients
Arm Type
Active Comparator
Arm Description
Patients stratified as low risk on penicillin provocation undergo a one dose full dose provocation test with 500mg amoxicillin
Arm Title
High risk
Arm Type
Active Comparator
Arm Description
Patient stratified as high risk undergo a full allergologic work up, and only some of these will undergo a provocation test.
Intervention Type
Diagnostic Test
Intervention Name(s)
Risk stratification
Intervention Description
advanced penicillin challenge after risk stratification
Primary Outcome Measure Information:
Title
Validating of a risk stratification tool ( in Norwegian) and advanced drug provocation challenge
Description
Negative predictive value of the risk stratification tool
Time Frame
trough study completion up to 3 years
Title
Analyzing the effects of risk stratification and advanced drug provocation
Description
Change in number of patients with antibiotic treatment in line with government recommendation.
Time Frame
Trough study completion up to 5 years
Title
Analyzing the gut microbiome of patient labeled penicillin allergic
Description
Map the gut microbiota profile in patients labeled penicillin allergic with 16S rRibosomal ribonucleic acid sequencing.
Time Frame
through study completion up to 3 years
Secondary Outcome Measure Information:
Title
Change in days submitted to hospital before and after delabeling in the current ward.
Description
number of days submittet to hospital
Time Frame
Through study completion up to 3 years
Title
Number of patients with treatment related adverse events on oral provocation testing.
Description
number of patients with treatment related adverse event on oral provocation testing.
Time Frame
trough study completion up to 3 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Penicillin allergy in the patient journal oder patient reported
Exclusion Criteria:
Not able to give concent. Under 16 years of age.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marie Alnæs
Phone
55 97 50 00
Email
marie.bjorbak.alnes@helse-bergen.no
First Name & Middle Initial & Last Name or Official Title & Degree
Torgeir Storaas, phd
Phone
55 97 50 00
Email
torgeir.storaas@helse-bergen.no
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Torgeir Storaas, phd
Organizational Affiliation
Regionalt senter for astma, allergi og annen overfølsomhet i Helse vest, Haukeland universitetssjukehus
Official's Role
Study Chair
Facility Information:
Facility Name
Haukeland University Hospital
City
Bergen
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marie Alnæs
Phone
55 97 50 00
Email
marie.bjorbak.alnes@helse-bergen.no
First Name & Middle Initial & Last Name & Degree
Marie Alnæs
Facility Name
Helse Førde
City
Førde
Country
Norway
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lars Sandven
Email
lars.sandven@helse-forde.no
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Penicillin Allergy Delabeling Project
We'll reach out to this number within 24 hrs